Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Daiichi and Sankyo signed an agreement to integrate their businesses on 13th May 2005. The joint holding company of Daiichi Sankyo was created on 28th September 2005, followed by the integration of pipelines from both companies and the start of a sales collaboration, in October 2005. The healthcare businesses of both companies were integrated into a single business in April 2006. The company expects to spin-off its non-pharmaceutical business by the end of March 2007. Full business integration was substantially completed by April 2007.

Market conditions in Japan are becoming increasingly fierce. Japan's medical insurance system is being reformed, with measures being taken to curb medical expenses, including the promotion of generic drug use and the April 2004 national health insurance drug price revisions. These developments, against a backdrop of rapid demographic change, with a falling birth rate and increasing numbers of aged citizens, and the possibility of drug price reform, could significantly affect Daiichi-Sankyo's business.

Sales of Daiichi-Sankyo's products continue to rise, albeit slowly. Although operating income has fallen noticeably this year, and net income fell in line with this, foreign sales have increased dramatically, up 51.1 per cent and now accounting for just over 28 per cent of all sales. Without this strong growth the negative impact of the Japanese market would have been felt even more strongly.

As a result of the merger, Daiichi-Sankyo is more able to react to the adverse market conditions in Japan. With its increased ability for investment, it plans to undertake a greater proportion of the development, sales and marketing of its products globally, with the consequent expected rise in profits. However, with many of its competitors pursuing similar strategies and the continued efforts of foreign pharma companies, the outlook is uncertain. With foreign sales now accounting for over a quarter of the companies revenue and home-based sales becoming increasing constricted by domestic government policies and competition from overseas-based companies, Daiichi-Sankyo must learn to look beyond its borders and continue to expand if it is to increase growth rates.

This new strategic analysis report Daiichi Sankyo: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.